⌛ Did you miss ProPicks’ 13% gains in May? Subscribe now & catch June’s top AI-picked stocks early.Unlock Stocks

Timeout From Q3 Earnings: GDP +2.9%

Published 10/27/2016, 10:17 PM
Updated 07/09/2023, 06:31 AM
MA
-
AN
-
XOM
-
ABBV
-

Friday, October 28, 2016

Taking a break for a moment from the Q3 earnings deluge — which continues, and will remain heavy next week and beyond — to report on our first read of Q3 Gross Domestic Product (GDP). At 2.9%, we are seeing a snap-back from below-trend growth earlier in the year, heating up higher than expectations. This is the highest read on GDP in two years.

Analysts had been starting to look at 3% growth in 2016 as something of a pipe dream lately, with the final read on Q2 GDP at a relatively paltry 1.4%. In fact, core GDP quarter over quarter is actually down from Q2 — 1.7% versus 1.8% last time.

So what accounts for this upswing? Exports are +10%. As economies in both developing and developed nations gain sounder footing, demand for U.S. products has grown, even with a stronger dollar in play. Where we see negative numbers are in things like equipment (-2.7%), which appears to have been affected by persistently low oil prices.

As a result, we see the 10-year bond yield inching upward to 1.8% — still way below historic averages, but higher than the 1.7% it had been stuck at all summer. As we continue to see economic metrics strengthening, we will keep our eye on things like the 10-year a bit more closely.

Q3 Earnings Plod Along

Exxon Mobil (NYSE:XOM) posted mixed Q3 earnings results — 63 cents per share beat the 60 cents we had expected, though revenues of $58.68 billion in the quarter was light the $60.56 billion in the Zacks consensus. The company’s barrels of oil equivalent produced per day was down 2.7%.

AutoNation (NYSE:AN) also missed top-line expectations, and came in 10 cents light on the bottom line, as well. $1.05 per share marks the second negative earnings surprise in the past four quarters. Takeda airbag problems that have hit the company’s supply chain persist.

Humira manufacturer AbbVie (NYSE:ABBV) just met earnings estimates of $1.21 per share while falling short of the $6.55 billion in sales, reporting $6.43 billion. The company did tighten its full-year earnings guidance to $4.80-4.82 per share.

Has anyone outperformed this morning? Sure — Mastercard (NYSE:MA) put up $1.08 per share, outpacing the 98 cents expected. Sales of $2.9 billion in the quarter topped the $2.74 billion in the Zacks consensus estimate.

Mark Vickery
Senior Editor

Click here to follow this author>>


AUTONATION INC (AN): Free Stock Analysis Report

EXXON MOBIL CRP (XOM): Free Stock Analysis Report

MASTERCARD INC (MA): Free Stock Analysis Report

ABBVIE INC (ABBV): Free Stock Analysis Report

Original post

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.